MedTrace Logo

Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods

NCT02657694 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2017-02-16

No results posted yet for this study

Summary

REDEMPTION (Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods) is observing and collating the treatment course, safety profile, and outcomes of patients around the world who are choosing to self import generic versions of the Direct Acting Antivirals Sofosbuvir, Ledipasvir and Daclatasvir from countries like China, India and Bangladesh.

Conditions

  • Hepatitis C

Interventions

DRUG

Sofosbuvir+Ledipasvir

DAA medication treatment

DRUG

Sofosbuvir+Daclatasvir

DAA medication treatment

DRUG

Sofosbuvir+Velpatasvir

DAA medication treatment

Sponsors & Collaborators

  • FixHepC

    lead OTHER

Principal Investigators

  • James Freeman, MB,BS,BSc · ACRRM

Eligibility

Min Age
18 Years
Max Age
82 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2017-01-01
Completion
2018-06-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02657694 on ClinicalTrials.gov